Weight Loss Drugs Could Deliver Billions to U.S. Economy, Goldman Says

The US economy could grow by 1% if 60 million Americans take GLP-1 weight loss drugs by 2028, according to Goldman Sachs estimates.

Poor health imposes economic costs through reduced labor supply, early deaths, and informal caregiving taking people out of the workforce.

GLP-1 drugs like Ozempic and Mounjaro have shown promise in improving health outcomes related to obesity and diabetes.

Wider usage of GLP-1 drugs could increase productivity by helping obese individuals work more and be more productive.

Goldman Sachs estimates 10-70 million Americans could be taking GLP-1 drugs by 2028, resulting in GDP growth exceeding current trends by 0.6-3.2%.